The German etanercept registry for treatment of juvenile idiopathic arthritis.
about
Consensus treatment plans for new-onset systemic juvenile idiopathic arthritisTreatment of juvenile idiopathic arthritis: a revolution in careWhat does an adult rheumatologist need to know about juvenile idiopathic arthritis?IL-1 Inhibition in Systemic Juvenile Idiopathic ArthritisJuvenile Idiopathic Arthritis: Diagnosis and TreatmentManaging cytokine release syndrome associated with novel T cell-engaging therapies.Summary of worldwide pediatric malignancies reported after exposure to etanercept.Follistatin-like protein 1 is a mesenchyme-derived inflammatory protein and may represent a biomarker for systemic-onset juvenile rheumatoid arthritis.Predictors of response to methotrexate in juvenile idiopathic arthritis.Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis.Toxicity management for patients receiving novel T-cell engaging therapies.A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.Etanercept biosimilarsCurrent evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs.Current medical treatments for juvenile idiopathic arthritis.2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.Diagnosis and management of adult onset Still's disease.Systemic arthritis in children: a review of clinical presentation and treatmentRates of malignancy associated with juvenile idiopathic arthritis and its treatmentMRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis.Evaluation of children with juvenile idiopathic arthritis in southeastern Turkey: a single center experience.Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent.Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade.Biologic therapies for inflammatory eye disease.Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature.TNFalpha blockade in human diseases: an overview of efficacy and safety.Emerging therapies offer new methods for treating rheumatoid arthritisDouble-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvementEtanercept treatment in juvenile idiopathic arthritis: the Polish registryEtanercept: long-term clinical experience in rheumatoid arthritis and other arthritis.Attainment of inactive disease status following initiation of TNF-α inhibitor therapy for juvenile idiopathic arthritis: enthesitis-related arthritis predicts persistent active diseaseBiological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.Challenges in the management of juvenile idiopathic arthritis with etanerceptCirculating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis.Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanerceptSystemic JIA: new developments in the understanding of the pathophysiology and therapy.Treatment strategies for juvenile idiopathic arthritis.Guidelines on the use of etanercept for juvenile idiopathic arthritis in Japan.
P2860
Q24610145-AB09A20E-FFFB-44E0-91B8-9211154A5F4CQ26849497-241F9199-39C3-49A4-BBDF-C30B5A7FE207Q26995394-2A1821F0-2FC7-4E2D-9A1A-EBDFFF20B1CFQ28078134-FDB48365-4E32-42CB-A7A7-B7E1F82A95F4Q28079246-D7F52DB2-D87B-4F4E-AE5F-6497BF980F8FQ33993517-80EE1F20-49E9-4EE1-B100-6A64D0C27F1DQ33998050-0463F5C0-E492-44ED-831E-0E33475B8BE2Q34063418-67B5E568-AD1A-4F91-A39E-E00430BEAE1BQ34069374-8425D781-D3FC-47A9-B1B6-9F23529B3088Q34196943-1C4F0B3A-6B24-467A-83C5-546E8018621AQ34343346-B79AEE77-A019-4173-B2C8-2EC1806033FAQ34632661-CFAA9ACF-D1AD-48C9-A1AE-971CD7D1EAB1Q35020358-1A4C3EED-EAF3-4BAD-8CE3-8AA3810E8D3BQ35150941-5DFA7EC8-A10C-4894-9800-7B2E4BE91CE4Q35294398-4821A347-D8F2-4374-BD05-F016259481F1Q35567870-7D64C6CD-1487-4AF2-B2CE-E9A32531D2CBQ35635172-EA10615C-11E6-4475-8D0C-DDEA9E511CAAQ35637158-BB44DC79-1766-45DF-88BF-9DAFEE057270Q35659928-87C80C5E-5D0A-4ACB-8A58-ACBAF16F0D13Q35861269-61C90CEA-CC9F-481F-9FC8-00A92CD6A651Q35926593-43327C50-8FC6-47F7-B4B0-698849C40781Q36071972-9E7F88A9-139B-4C64-94CF-E12A35ECD90AQ36183846-C67E2444-A5D1-4A98-92DF-54FE695568E4Q36403583-EC5C962E-83AA-43F1-9219-7F1C3B365052Q36501675-655A89DA-2407-44D5-871A-4E37036E5A9AQ36502928-82C1F001-7BE7-4399-B355-4C18416D2EF4Q36536861-ECF6FC56-8F48-409D-A605-DAEFB27C73F5Q36606216-1EC976A6-2971-4B29-93C4-69BA65D00AC8Q36633259-2F6B7D8C-EB55-4825-9146-2BEBA7EDC68BQ36771435-AEA68EA2-3842-4883-98C0-D474C7155A6DQ36847326-1946459F-E029-416B-91D9-A636B8C63D94Q37133996-E08E7ADF-8232-4E48-B83B-CAC0B8A3C779Q37290665-C5433A0C-564C-469C-AF7E-B4E6A864E24CQ37303219-FCABD69B-EB0D-4DAF-9F4C-749DBA83D6B3Q37343947-98AC3CB5-7728-4FCD-B1FF-320B36CACFE7Q37436386-5C05E860-36E9-4DB6-B40D-498DC85CB342Q37518319-E7493BBD-B511-4851-9315-5C56B79170CCQ37620829-6F24E5C0-9766-4728-B6C8-779EAA89D188Q37642763-7D8BCCB5-AAA0-4CC8-ACCF-FD87B4DEA0AAQ37678277-4C0606E3-34BA-4AD9-92F1-F54B321B5CC0
P2860
The German etanercept registry for treatment of juvenile idiopathic arthritis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The German etanercept registry for treatment of juvenile idiopathic arthritis.
@ast
The German etanercept registry for treatment of juvenile idiopathic arthritis.
@en
type
label
The German etanercept registry for treatment of juvenile idiopathic arthritis.
@ast
The German etanercept registry for treatment of juvenile idiopathic arthritis.
@en
prefLabel
The German etanercept registry for treatment of juvenile idiopathic arthritis.
@ast
The German etanercept registry for treatment of juvenile idiopathic arthritis.
@en
P2093
P2860
P356
P1476
The German etanercept registry for treatment of juvenile idiopathic arthritis.
@en
P2093
B Rogalski
H I Huppertz
H J Girschick
H Schmeling
I Foeldvari
P2860
P304
P356
10.1136/ARD.2003.014886
P407
P577
2004-04-28T00:00:00Z